Candel Therapeutics Inc(CADL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.41 | Insider Own | 19.83% | Shs Outstand | 76.1M | Perf Week | 3.58% |
| Market Cap | 0.66B | Forward P/E | - | EPS next Y | 18.19% | Insider Trans | -2.05% | Shs Float | 61.3M | Perf Month | -20.31% |
| Enterprise Value | 0.51B | PEG | - | EPS next Q | -0.34 | Inst Own | 61.15% | Short Float | 20.82% | Perf Quarter | -12.16% |
| Income | -0.09B | P/S | - | EPS this Y | -88.63% | Inst Trans | 10.21% | Short Ratio | 10.98 | Perf Half Y | 40.29% |
| Sales | 0.00B | P/B | 5.23 | EPS next 5Y | - | ROA | -56.37% | Short Interest | 12.77M | Perf YTD | 53.45% |
| Book/sh | 1.66 | P/C | 3.29 | EPS past 3/5Y | -3.41% -3.52% | ROE | -81.84% | 52W High | -38.07% ($14.00) | Perf Year | 54.82% |
| Cash/sh | 2.63 | P/FCF | - | Sales past 3/5Y | - | ROIC | -50.54% | 52W Low | 99.31% ($4.35) | Perf 3Y | 863.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -108.75% | Gross Margin | - | Volatility(W/M) | 7.3% 5.98% | Perf 5Y | -22.93% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.09 | EPS Q/Q | -463.69% | Profit Margin | - | RSI (14) | 41.13 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.09 | Sales Q/Q | - | SMA20 | -4.42% ($9.07) | Beta | -0.31 | Target Price | $22.11 |
| Payout | - | Debt/Eq | 0.39 | Earnings | 2026/8/13 | SMA50 | -20.15% ($10.86) | Rel Volume | 0.57 | Prev Close | $8.25 |
| Employees | 55 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | -118.58% - | SMA200 | 4.98% ($8.26) | Avg Volume(3M) | 1.16M | Price | $8.67 |
| IPO | 2021/7/27 | Option/Short | Yes/Yes | Trades | 7817 | Volume | 663,882 | Change | 5.09% |
🧬 Candel Therapeutics (ticker: CADL) is a clinical-stage biotech company developing virus-based multi-modal immunotherapies. It focuses on a viral immunotherapy pipeline that stimulates the tumor microenvironment to induce immune responses in cancer patients, and is headquartered in the United States and listed on NASDAQ.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
CADL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -88.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -22.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #196 of 594 in the industry
Based on market cap of $663M.
DBVT#194 DBV Technologies ADR $669M PER - 
AURA#195 Aura Biosciences Inc $664M PER - CADL#196 Candel Therapeutics Inc $663M PER - 
LXRX#197 Lexicon Pharmaceuticals Inc $661M PER - 
OLMA#198 Olema Pharmaceuticals Inc $655M PER - 
FAQ
What kind of company is CADL?
CADL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CADL?
The market cap of CADL is approximately $663M, ranking 2,936 within its sector.
What is the 52-week high and low for CADL?
CADL has recorded a 52-week high of $14.00 and a low of $4.35.
